Cost sharing: implications of a well-intended benefits strategy

J Manag Care Spec Pharm. 2022 Feb;28(2):275-277. doi: 10.18553/jmcp.2022.28.2.275.

Abstract

DISCLOSURES: The thoughts and opinions expressed in this article are those of the author only and are not the thoughts and opinions of any current or former employer of the author. Nor is this publication made by, on behalf of, or endorsed or approved by any current or former employer of the author.

MeSH terms

  • Cost Control
  • Cost Sharing / economics*
  • Drug Costs*
  • Health Literacy
  • Health Services Research
  • Humans
  • Insurance, Pharmaceutical Services / economics*
  • United States